Libra Infusions Limited published its three-quarters financial statement from the July to March period of FY22, whereas the company posted impressive profit growth compared to the previous FY.
A taxpayer could not deduct purported business expenses associated with writing and research activities held to be not engaged in for profit under Sec. 183.